Luseogliflozin

Research use only, not for human use.

A potent, selective, orally acitve SGLT2 inhibitor with IC50 of 2.26 nM, 1650-fold selectivity over SGLT1.

A potent, selective, orally acitve SGLT2 inhibitor with IC50 of 2.26 nM, 1650-fold selectivity over SGLT1; exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in vivo; increases urinary glucose excretion in Zucker fatty rats and beagle dogs at doses of 0.3 and 0.03 mg/kg respectively; improves glucose tolerance without stimulating insulin secretion and reduces hyperglycaemia in STZ-induced diabetic rats.Diabetes Approved.

Luseogliflozin (TS-071, 3p) is a potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM); Luseogliflozin has the protential for treating type 2 diabetes.

Luseogliflozin (1 mg/kg, p.o.) exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in rats and dogs.

TS-071 | TS071

GPCR/G Protein

SGLT

SGLT

Metabolic Disease

Diabetes

898537-18-3

434.547

C23H30O6S

>98% (HPLC)

——

O[C@H]([C@H]([C@@H]([C@H]1CO)O)O)[C@@H](S1)C2=CC(CC3=CC=C(OCC)C=C3)=C(C)C=C2OC

(2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-trio

(-20℃)

With Ice Pack

≥ 2 years